Neuromod and Treble Health Partner to Expand Lenire Access

The partnership makes the Lenire device for tinnitus available through Treble Health clinics in Philadelphia and Charlotte.

Feb. 24, 2026 at 5:55pm

Got story updates? Submit your updates here. ›

Neuromod Devices Ltd has partnered with Treble Health to expand the availability of the Lenire tinnitus treatment device for patients in Philadelphia and Charlotte. The collaboration provides patient access to Lenire through two Treble Health network practices: Audiology & Hearing Services of Charlotte and The Tinnitus Treatment Center of Philadelphia.

Why it matters

This partnership aims to increase awareness and accessibility of the Lenire device, a bimodal neuromodulation treatment for tinnitus, to more patients in the United States. Tinnitus is a common condition that can significantly impact quality of life, and expanding treatment options is important for those suffering from this condition.

The details

Lenire is a bimodal neuromodulation device that combines audio tones delivered through headphones with mild electrical pulses delivered to the tongue's surface via a proprietary Tonguetip device. Patients with bothersome tinnitus typically use the device at home for two 30-minute sessions daily for approximately 12 weeks. A recent study found that 81.8% of patients with moderate or worse tinnitus demonstrated a clinically significant improvement after about 12 weeks of treatment with Lenire.

  • The partnership was announced on February 19, 2026.

The players

Neuromod Devices Ltd

A medical device company that developed the Lenire tinnitus treatment device.

Treble Health

A hearing health service specializing in tinnitus treatment that operates a hybrid care model of telehealth and in-person clinics.

Audiology & Hearing Services of Charlotte

A Treble Health network practice that will offer the Lenire device to patients.

The Tinnitus Treatment Center of Philadelphia

A Treble Health network practice that will offer the Lenire device to patients.

Eric Timm

President, global commercial operations & CEO, Neuromod USA Inc.

Got photos? Submit your photos here. ›

What they’re saying

“Expanding the awareness and availability of Lenire to tinnitus patients in the USA and globally is a priority for Neuromod. I'm delighted this partnership with Treble Health will give people living with tinnitus broader access to treatment with Lenire supported by guidance from expert clinicians.”

— Eric Timm, President, global commercial operations & CEO, Neuromod USA Inc (Neuromod)

“The Lenire device has been an outstanding addition to our tinnitus treatment options as clinicians. It gives us another intervention that has proven to benefit the vast majority of tinnitus patients. I am delighted to make it available to my patients as part of Treble Health.”

— Gail Brenner, Tinnitus specialist at The Tinnitus Treatment Center of Philadelphia (Treble Health)

“I'm delighted to make Lenire available to tinnitus patients at these two Treble Health in-person clinics. Since Lenire's De Novo approval by the US FDA in 2023 we have seen evidence of great treatment outcomes for patients be peer-reviewed and published in respected scientific journals. These results make it clear that Lenire is an extremely strong treatment option for tinnitus patients.”

— Ben Thompson, Founder of Treble Health (Treble Health)

What’s next

The Lenire device will now be available to tinnitus patients through the Treble Health clinics in Philadelphia and Charlotte.

The takeaway

This partnership between Neuromod and Treble Health aims to increase access to the Lenire bimodal neuromodulation device, a promising new treatment option for those suffering from chronic tinnitus, by making it available through specialized tinnitus clinics in two major US cities.